Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Businesswire News Releases

Oct 14, 2019 01:00 ET
Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test
Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the response in patients with neuroendocrine tumors (NET) treated with Alpha and Beta Peptide Receptor Radionuclide Therapy (PRRT)....
Oct 14, 2019 01:00 ET
Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF), in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF, with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm (p
Oct 14, 2019 00:49 ET
Liberty Global Announces CHF 500 Million Conditional Rights Purchase Commitment for Sunrise’s Financing of UPC Switzerland Acquisition
Liberty Global plc (“Liberty Global”) (NASDAQ: LBTYA, LBTYB and LBTYK) and Sunrise Communications AG (“Sunrise”) today announced an agreement whereby Liberty Global will support Sunrise’s rights offering related to the acquisition of UPC Switzerland1....
Oct 14, 2019 00:05 ET
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 millio...
Oct 14, 2019 00:01 ET
ABOM® HEET Receives APEL® Approval
Abom, Inc. is proud to announce that it is now Authorized Protective Eyewear List (APEL) approved for its successful ABOM HEET® active anti-fog tactical eyewear goggle system. ABOM successfully completed U.S. ARMY – Product Manager Soldier Protective Equipment (PM SPE) audit and full compliance review for APEL qualification in May 2019. Our ABOM HEET Goggle platform met al...
Oct 14, 2019 00:01 ET
BIZCENTER USA Launches Coworking Facility in Orlando With Plans for Nationwide Franchise
Multimedia, Inc. (www.multimediausa.com) starts today the operations of BIZCENTER USA LLC, its affiliate for shared workspaces and virtual offices. Located on a fully owned 4,400 sq. ...
Oct 13, 2019 21:00 ET
BrainChip Announces the Akida™ Development Workshop
BrainChip Holdings Ltd (ASX: BRN), a leading provider of ultra-low power, high performance edge AI technology, today announced a neural networking workshop using the Akida™ Development Environment (ADE). Qualified developers and data scientists are invited to attend the workshop on 1 November 2019 at the Ernst & Young facility at Tank Stream Labs, EY Off...
Oct 13, 2019 21:00 ET
Vodafone Idea and Mavenir Partner to Extend Network as a Platform
Mavenir, the industry's only end-to-end cloud-native 4G and 5G network software provider for CSPs today announced the extension of its partnership with Vodafone Idea Limited (VIL), India’s leading telecom operator, to extend VIL Network as a Platform, reaching distributed presence across all the major Industrial, Commercial, and Services clusters in India....
Oct 13, 2019 17:32 ET
ConocoPhillips Announces Agreement to Sell Interests in Australia-West for $1.39 Billion
ConocoPhillips (NYSE: COP) today announced it has entered into an agreement to sell the subsidiaries that hold its Australia-West assets and operations to Santos for $1.39 billion, plus customary closing adjustments. In addition, the company will also receive a payment of $75 million upon final investment decision of the Barossa development project. The subsidiaries hold the company’s 37.5 percent interest in the Barossa project and Caldita Field, its 56.9 percent interest in the Darwin LNG facility and Bayu-Undan Field, its 40 percent interest in the Poseidon Field, and its 50 percent interes...
Oct 12, 2019 22:08 ET
PSPS Update: All Customers Impacted by Safety Shutoffs Have Now Been Restored
Pacific Gas and Electric Company (PG&E) said that every customer impacted by the Public Safety Power Shutoff (PSPS) had their power restored as of Saturday afternoon....
Oct 12, 2019 18:53 ET
PSPS Update: More than 99.5 Percent of Customers Impacted by Safety Shutoffs Have Been Restored System-Wide
Pacific Gas and Electric Company (PG&E) said Saturday that more than 99.5 percent of customers impacted by the Public Safety Power Shutoff (PSPS) that began on Wednesday now have their power restored....
Oct 12, 2019 18:48 ET
Health Net Assisting Members in Los Angeles and Riverside Counties During State of Emergency
In response to Gov. Gavin Newsom’s declared states of emergency in Los Angeles and Riverside Counties, Health Net, LLC is providing special assistance to ensure Health Net members affected by ongoing wildfires have access to essential prescription medications, critical Health Net information, and other healthcare services to help them cope with grief, loss, stres...
Oct 12, 2019 17:14 ET
Governor Newsom Makes California the First State to Ban the Sale and Manufacture of New Fur
Governor Newsom has signed Assembly Bill 44, the California State Fur Ban, into law today....
Oct 12, 2019 16:56 ET
Campus France Launches a New International Communication Campaign, Giving Voice to Those Who Have Chosen France for Their Studies
Campus France is launching an unprecedented communication campaign to promote the excellence of French educational institutions and their courses around the world....
Oct 12, 2019 13:00 ET
Nonprofit CureDuchenne Launches Biobank to Fuel Research for Duchenne Muscular Dystrophy
CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (Duchenne), announced today it has initiated the development of a biobank for Duchenne. The CureDuchenne Biobank is dedicated to empowering Duchenne research and the search for a cure for Duchenne that is independent and accessible to all researchers....
Oct 12, 2019 10:00 ET
Topcon Healthcare Selected to Ease Transition for IBM® Merge Eye Station and Merge Eye Care PACS Customers
Topcon Healthcare Solutions, a leading provider of medical devices and software solutions for the eye care community, announced today that it is partnering with IBM Watson Health Imaging in an effort to support a transition plan for their Merge Eye Station™ digital fundus imaging platform and the Merge Eye Care PACS™ web-based image management system, two products from their global eye care division that are being end-of-lifed ("EOL") as announced previously....
Oct 12, 2019 04:45 ET
Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD). Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to placebo. Safety data showed that both evaluated doses of abrocitinib (200mg and 100mg) were well tolerated and were consistent with a companion study (JADE MONO-2) from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) gl...
Oct 12, 2019 03:15 ET
Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Patients in the study treated with either 8 mg twice-daily or 12...
Oct 12, 2019 02:32 ET
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
Incyte (Nasdaq:INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients with vitiligo....
Oct 12, 2019 02:28 ET
PSPS Update: 98 Percent of Customers Have Been Restored System-Wide
Pacific Gas and Electric Company reported Friday at 10:30 p.m. that 98 percent of customers impacted by Public Safety Power Shutoff (PSPS) have had their power restored. Fewer than 13,000 customers remain without power due to the PSPS....